The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2021]

Author(s):

1. Serhat Ozçelik: Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lütfi K1rdar City Hospital,Turkey

2. Mehmet Celik: Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Trakya University Edirne,Turkey

3. Aski Vural: Department of Internal Medicine, Ad1yaman Training and Research Hospital,Turkey

4. Bunyamin Aydin: Department of Endocrinology and Metabolic Diseases, Ad1yaman Training and Research Hospital,Turkey

5. Hulya Gozu: Marmara University Training and Research Hospital, Department of Endocrinology and Metabolism,Istanbul,Turkey

Abstract:

Objective: To determine the relationship between the positivity of third-generation TSH receptor antibody (TRAb) at the time of diagnosis and the cumulative methimazole dose used until remission in patients with Graves disease. Study Design: Cross-sectional, descriptive study. Place and Duration of Study: Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lüt K1rdar City Hospital, Turkey from 2016 to 2018. Methodology: Newly diagnosed Graves' patients were included in the study. The patients were divided into two groups according to whether they entered remission (n: 21) or not (n: 20), in the 18th month of methimazole treatment. In addition, the patients were further divided into two categories, according to TRAb status at the time of diagnosis as negative (n: 17) or positive (n: 24). The TRAb positivity and the cumulative methimazole dose they used until the month of remission were compared in these groups. Results: The mean time to reach remission in 41 patients was 20.5 ± 3.1 months. TSH receptor antibody positivity rate was 58.5%. When the TRAb positivity of the groups was compared according to the state of having remission in the 18th month of the treatment, the positivity rate in the non-remission group was statistically signi cantly higher (p = 0.023T)h.e time to go into remission was longer and the cumulative methimazole dose requirement was higher in the TRAb positive group (p <0.001). Conclusion: Graves disease patients with positive third-generation TRAb were found to have a lower rate of remission in the 18month period compared to negative patients.

Page(s): 517-522

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 5, Year: 2021

Keywords:

methimazole , Cumulative , Graves disease , TSH receptor antibody

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views